Can we harness the power of the immune system to cure childhood cancer? Neuroblastoma
is one of the most common solid tumours to occur in children, predominantly affecting children under the age of five years. We heard first-hand from Dr Guy Makin, a Paediatric Oncologist at Royal Manchester Children’s Hospital, of the difficulties inherent in treating young patients. Around 40 per cent of them have a high-risk form that is incurable using conventional treatments (chemotherapy
approaches, turning the power of the immune system against the tumour, have already shown considerable promise in the treatment of neuroblastoma. Dave and colleagues are working on techniques that should improve the effectiveness of current immunotherapy techniques by enhancing the tumour-killing ability of the modified immune cells. The aim is to improve survival in young patients with neuroblastoma.